4CPS-060 Abstract withdrawn

<h3>Background and Importance</h3> Real-world data on long-term treatment patterns associated with guselkumab and secukinumab in plaque psoriasis are lacking. <h3>Aim and Objectives</h3> The aim was to compare the real-world persistence, effectiveness, and safety of guselkumab and secukinumab in adult patients with moderate to severe psoriasis in two different hospitals. <h3>Material and Methods</h3> Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015 to June 2024). Adults with moderate to severe psoriasis who initiated guselkumab or secukinumab were identified and followed-up until June 2024, or disenrollment. Baseline demographic: sex, age at diagnosis, weight, prior failed treatments, duration of treatment and psoriasis area severity index score (PASI). Exclusion criteria: patients with psoriatic arthritis. Adherence was measured using medication possession ratio (MPR); patients with MPR ≥ 80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of guselkumab and secukinumab were collected. Persistence on guselkumab and secukinumab was calculated based on the dates of initiation and end of treatment. Biologic treatment persistence was estimated using the Kaplan-Meier method with 1-year intervals, and comparisons were made using the <i>log-rank</i> test. <h3>Results</h3> A total of 62 guselkumab and 88 secukinumab patients with moderate to severe psoriasis were included, of whom 18 (29%) guselkumab and 45 secukinumab (51.1%) had not received prior biological treatment. Guselkumab baseline PASI score was 15.4 ± 1,7 and patients received 1.9 ± 0.9 prior biological treatments. Secukinumab baseline PASI score was 15.0 ± 2.9 and patients received 1.4 ± 0.8 prior biological treatments. 5 (8.1%) patients discontinued guselkumab treatment due to the following reasons: lack of effectiveness (4.8%), transaminase elevation (1.6%) and pregnancy (1.6%). 34 (38.6%) patients discontinued secukinumab treatment due to the following reasons: 19 (21.5%) due to a lack of effectiveness, 7 (7.9%) due to adverse effects. Guselkumab persistence was 21.6 ± [2.0] months for all patients. Secukinumab persistence was 61.5 ± [21.7] months for all patients. Guselkumab persistence at 1 year, 2 years and 3 years was 98.4%, 95.6% and 91.8%, respectively. Secukinumab persistence at 1 year, 2 years and 3 years was 72.7%, 51.1% and 39.8%, respectively. <h3>Conclusion and Relevance</h3> Over 36 months, guselkumab patients exhibited better persistence and a lower discontinuation rate than secukinumab patients in real-world settings. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest